SecBot SecBot
6-K ·Filed Jul 14, 2026

MESO

MESOBLAST LTD
BULLISH
Impact 6/10
Horizonmonths Processed4mo ago SEC0001345099-26-000066
Notable filing: 6-K
Actionable Insight ▲ Bullish

The enrollment completion is a positive operational milestone, but the stock may have limited near-term catalyst until top-line data in mid-2027. Monitor for any Data Safety Monitoring Board updates or early signals. Traders should weigh the long timeline against the large addressable market.

DirectionBullish
Confidencehigh
Horizonmonths

rexlemestrocel-L

▲ Bullish Named in this 6-K
Impact
Phase
Phase 3 / Filed BLA
Time to market
LVAD/heart failure BLA now under FDA review with modular review requested — no PDUFA date set yet (potentially 2027 if accepted). CLBP indication likely 2028 at earliest (topline mid-2027, BLA Q3 2027, FDA action 2028).
Next catalyst
None dated

What to watchMesoblast just filed a BLA for rexlemestrocel-L in LVAD/heart failure, the next catalyst is FDA acceptance and a PDUFA date. Meanwhile, the much larger CLBP opportunity (7M+ US patients, non-opioid approach) is advancing with Phase 3 enrollment complete and topline due mid-2027. The company already generates real revenue from Ryoncil (~$110-120M FY2026 guidance), de-risking the story vs. pre-revenue biotechs. Monitor (1) FDA's action on the LVAD BLA modular review, (2) CLBP Phase 3 topline in mid-2027, and (3) Ryoncil revenue growth trajectory.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$16.74
T+0 close · Jul 14, 2026 · via day close
Latest settled
−16.73%
T+60 · $13.94
Vs SPY
−20.10%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 14 $16.74entry
  2. T+1 · 4mo ago +8.96%α +8.56% · $18.24
  3. T+5 · 4mo ago −0.66%α +0.64% · $16.63
  4. T+20 · 3mo ago +1.08%α −1.42% · $16.92
  5. T+60 · 6w ago −16.73%α −20.10% · $13.94
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mesoblast announced it has enrolled the target of 300 patients in the pivotal Phase 3 trial (MSB-DR004) of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease. Top-line results are expected in mid-CY2027. The trial has RMAT designation from the FDA, and the company is proceeding with commercial manufacturing in parallel. This milestone de-risks the program but does not provide efficacy data.

Key Facts

  • At least 300 patients treated in the placebo-controlled pivotal Phase 3 trial of rexlemestrocel-L for CLBP.
  • Top-line results expected in mid-CY2027 after the last patient completes 12-month follow-up.
  • Rexlemestrocel-L has FDA RMAT designation, providing eligibility for priority review upon BLA filing.
  • Management estimates potential peak year revenue of >$10 billion with single-digit market penetration (forward-looking statement).
  • The trial is powered to show significant difference in pain reduction at 12 months vs. sham control.

Financial Impact

No current financial data filed. Management projects potential peak revenue >$10B for this indication, but this is a forward-looking estimate.

Risk Factors

  • Trial failure to meet primary endpoint could severely impair the program.
  • Regulatory delays or additional data requirements from FDA.
  • Competition from other non-opioid pain treatments.
  • Dilution risk if Mesoblast needs to raise capital to fund commercial launch.

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001345099-26-000066
Exhibit: exhibit991clbppivotaltri.htm0001345099-26-000066
Document: 0001345099-26-000066-index-headers.html0001345099-26-000066
Document: 0001345099-26-000066-index.html0001345099-26-000066
Document: 0001345099-26-000066.txt0001345099-26-000066

Track record

25 reports on MESO

Performance horizon

6 of 14 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 9 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
  2. Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
  3. Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
  4. Oct 29, 202618d ago 6-K Bullish 6/10 No price data
  5. Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
  6. Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
  7. Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
  8. Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
  9. Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
  10. Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 14, 2026